GATC Health’s Derisq® AI Report Highlighted in The Scientist’s 2026 Top Innovations Feature

IRVINE, Calif., November 6, 2026 – This week, The Scientist released a dedicated follow-up feature, “Top Innovations Startup Winners: Interactomics, Cell Therapy Analysis, and Drug Risk,” prominently highlighting our Derisq® AI risk and prioritization report. Built on our proprietary Operon® platform, Derisq predicts a drug candidate’s safety, efficacy, and off-target risks before development capital is committed.

As the article outlines, Derisq reduces the inherent risk of drug development by evaluating efficacy, safety, pharmacokinetics, and patient selection before committing to costly clinical trials. Derisq translates these complex biological variables into an actionable probability-of-technical-success (PTS) assessment. 

As our Co-founder, Chairman, and CTO, Jayson Uffens, explained in the feature: “Before credit scores, creditworthiness was decided lender by lender, inconsistently. The score replaced that with a common, comparable standard for risk. Derisq does the same thing for a drug asset, before the real capital is committed.” 

The article also highlights the real-world value of Derisq through the perspective of David J. Mazzo, Ph.D., President and CEO of Lisata Therapeutics. Dr. Mazzo noted that Derisq adds a highly predictive layer to development strategy and portfolio prioritization by focusing on biological insight rather than correlation alone. “What excites me most is that GATC’s technology is trying to solve a very real problem in drug development: we still make too many critical decisions with incomplete biological insight,” he shared.